GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DMS Imaging SA (XBRU:ALIMG) » Definitions » Debt-to-EBITDA

DMS Imaging (XBRU:ALIMG) Debt-to-EBITDA : -242.18 (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is DMS Imaging Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

DMS Imaging's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €6.06 Mil. DMS Imaging's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €11.86 Mil. DMS Imaging's annualized EBITDA for the quarter that ended in Dec. 2023 was €-0.07 Mil. DMS Imaging's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -242.18.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for DMS Imaging's Debt-to-EBITDA or its related term are showing as below:

XBRU:ALIMG' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -11.7   Med: -0.12   Max: 8.86
Current: 8.86

During the past 12 years, the highest Debt-to-EBITDA Ratio of DMS Imaging was 8.86. The lowest was -11.70. And the median was -0.12.

XBRU:ALIMG's Debt-to-EBITDA is ranked worse than
86.5% of 274 companies
in the Biotechnology industry
Industry Median: 1.325 vs XBRU:ALIMG: 8.86

DMS Imaging Debt-to-EBITDA Historical Data

The historical data trend for DMS Imaging's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DMS Imaging Debt-to-EBITDA Chart

DMS Imaging Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.32 -7.75 6.40 -11.70 8.86

DMS Imaging Semi-Annual Data
Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.14 -5.01 39.85 4.35 -242.18

Competitive Comparison of DMS Imaging's Debt-to-EBITDA

For the Biotechnology subindustry, DMS Imaging's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DMS Imaging's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DMS Imaging's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where DMS Imaging's Debt-to-EBITDA falls into.



DMS Imaging Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

DMS Imaging's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(6.058 + 11.863) / 2.022
=8.86

DMS Imaging's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(6.058 + 11.863) / -0.074
=-242.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


DMS Imaging  (XBRU:ALIMG) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


DMS Imaging Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of DMS Imaging's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


DMS Imaging (XBRU:ALIMG) Business Description

Traded in Other Exchanges
Address
7 Rue des Chasseurs Ardennais, Liege, BEL, 4031
DMS Imaging SA is a clinical-stage biopharmaceutical company. The company is engaged in the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies, based on its ASIT+ technology platform. Its lead product is gp-ASIT+, a phase III trial for the treatment of grass pollen rhinitis. Its pipeline products consist of hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy.

DMS Imaging (XBRU:ALIMG) Headlines

No Headlines